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Abstract
Background: There is still limited information on systemic inflammation in alpha-1-antitrypsin-deficient (AATD)
COPD patients and what effect alpha-1-antitrypsin augmentation therapy and/or exercise might have on circulating
inflammatory cytokines. We hypothesized that AATD COPD patients on augmentation therapy (AATD + AUG) would
have lower circulating and skeletal muscle inflammatory cytokines compared to AATD COPD patients not receiving
augmentation therapy (AATD-AUG) and/or the typical non-AATD (COPD) patient. We also hypothesized that cytokine
response to exercise would be lower in AATD + AUG compared to AATD-AUG or COPD subjects.
Methods: Arterial and femoral venous concentration and skeletal muscle expression of TNFα, IL-6, IL-1β and CRP were
measured at rest, during and up to 4-hours after 50% maximal 1-hour knee extensor exercise in all COPD patient groups,
including 2 additional groups (i.e. AATD with normal lung function, and healthy age-/activity-matched controls).
Results: Circulating CRP was higher in AATD + AUG (4.7 ± 1.6 mg/dL) and AATD-AUG (3.3 ± 1.2 mg/dL) compared to
healthy controls (1.5 ± 0.3 mg/dL, p < 0.05), but lower in AATD compared to non-AATD-COPD patients (6.1 ± 2.6 mg/dL,
p < 0.05). TNFα, IL-6 and IL-1β were significantly increased by 1.7-, 1.7-, and 4.7-fold, respectively, in non-AATD COPD
compared to AATD COPD (p < 0.05), and 1.3-, 1.7-, and 2.2-fold, respectively, compared to healthy subjects (p < 0.05).
Skeletal muscle TNFα was on average 3–4 fold greater in AATD-AUG compared to the other groups (p < 0.05). Exercise
showed no effect on these cytokines in any of our patient groups.
Conclusion: These data show that AATD COPD patients do not experience the same chronic systemic inflammation
and exhibit reduced inflammation compared to non-AATD COPD patients. Augmentation therapy may help to improve
muscle efflux of TNFα and reduce muscle TNFα concentration, but showed no effect on IL-6, IL-1β or CRP.
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Background
Alpha-1 antitrypsin deficiency (AATD) is an inherited
genetic disorder that leads to development of emphysema
resulting in chronic obstructive pulmonary disease (COPD)
among other complications (e.g. liver dysfunction). The
lack of functional α1-antitrypsin exposes the lungs to an
insufficient inhibition of serine protease activity leading to
chronic uncontrolled proteolytic attack that results in
early-life (<40 years of age) alveolar destruction, which can
occur independent of environmental risk factors, such as
cigarette smoke. Since the first report identifying the
connection between abnormal alpha-1 antitrypsin and
COPD in 1963 [1], more than 90 different α1-antitrypsin
phenotypes have been described. The most common
protein inhibitor (Pi) variants are the M, S, and Z alleles,
with the PiMM representing normal genotype and PiMS,
PiSS, PiMZ, PiZS and PiZZ representing genotypes of
increasing severity for abnormal circulating α1-antitrypsin
concentration (ranging from 20% loss in PiMS to >85%
loss in PiZZ individuals) [2]. The rates of decline in lung
function and onset of emphysema can be highly variable in
AATD individuals, in part due to phenotypic differences in
α1-antitrypsin reductions; but also due to varying individual
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exposures to environmental risk factors (most notably
cigarette smoke history) [3,4].
In people with normal circulating AAT levels, environ-
mental irritants (such as cigarette smoke, coal dust, etc.)
induces acute and chronic airway inflammation that plays
a prominent role in development and progression of
COPD [5]. Systemic inflammation is also prevalent in
many patients with COPD [6,7], but it remains controver-
sial whether systemic inflammation represents ‘spill over’
from the lung inflammation or activation of a chronic
systemic process [8]. Irrespective of the source, elevated
circulating levels of inflammatory biomarkers, such as
tumor necrosis factor-alpha (TNFα), C-reactive protein
(CRP), interleukin (IL)-6, and IL-1β have all been associated
with severity and exacerbations of COPD and may
contribute to comorbidities accompanying COPD [9-11].
In patients with AATD COPD, there is evidence that
abnormal alleles of α1-antitrypsin can produce polymers
that can act as neutrophil chemoattractants (such as Pi‘Z’
polymers) which may contribute to a pro-inflammatory
state and development of emphysema [12,13], and is
consistent with increased expression of pulmonary
inflammatory mediators in AATD individuals [14-16].
In addition, PiMZ subjects without airway obstruction
may also exhibit neutrophilic inflammation in their
airways, and therefore at greater risk in developing
pulmonary changes [15]. Indeed, native α1-antitrypsin
(AAT) serves as an endogenous inhibitor of proinflamma-
tory cytokine production [17,18], implying that loss or
reductions in AAT concentration could make AATD
individuals more susceptible to chronic systemic inflam-
mation. Management of AATD patients with COPD can
also include treatment with purified AAT to replace/
augment circulating AAT levels, commonly referred to
as ‘augmentation therapy’. Some evidence suggests that
augmentation therapy may reduce airway inflammation
[14,19-22] and potentially decrease the progression of
COPD symptoms [23]. To our knowledge, however,
there are no studies that have compared circulating
and skeletal muscle inflammatory cytokines in AATD
patients ‘on’ versus ‘off ’ augmentation therapy, or in
individuals with AATD with normal lung function.
Exercise is commonly prescribed as part of the medical
treatment plan for patients with COPD. While the benefits
of exercise to the immune system [24] and to cardiovascular
health are widely recognized, exercise is also known to
stimulate increases in pro-inflammatory cytokines, such as
TNFα and IL-6 [25]. In healthy individuals, the magnitude
and duration of these increases are off-set by similar
increases in anti-inflammatory cytokines [25-27]. One
concern for patients with COPD is that the combination
of exercise and an already elevated circulating inflamma-
tory cytokine level may prove more harmful than good.
Previous studies have reported on the effects of exercise
and expression of circulating inflammatory mediators
in non-AATD patients with COPD showing either in-
creased [28-31] or no change [32-36] in circulating
cytokines with exercise. No studies, thus far, have
assessed these responses to exercise in AATD indi-
viduals with or without COPD, and whether or not
augmentation therapy affects the circulating and/or
skeletal muscle expression of inflammatory cytokines
response to exercise.
Accordingly, to better understand the potential influence
of augmentation therapy on biomarkers of systemic
inflammation, and the relative risk of exercise contributing
to chronic systemic inflammation in AATD individuals, we
examined systemic expression of several key inflammatory
cytokines in AATD COPD patients receiving and not
receiving augmentation therapy, as well as AATD
individuals without evidence of obstructive airway disease.
Our evaluation also included two control groups:
non-AATD COPD patients (with normal α1-antitrypsin
levels), and age-matched healthy control subjects. We
hypothesized, under resting conditions, α1-antitrypsin
replacement therapy in AATD patients would result
in lower expression of circulating and skeletal muscle
inflammatory cytokines, compared to the other AATD
individuals and/or the traditional (non-AATD) COPD
patients. We also hypothesized that circulating cytokine
response to exercise would be lower in AATD patients
receiving α1-antitrypsin replacement therapy compared to
COPD or the other AATD subjects.
Methods
Subjects
AATD subjects (n = 16) were recruited by a national
advertisement campaign in the US and brought to the
Human Research Laboratory at the Division of Physiology,
University of California, San Diego. Exclusion criteria
included history of lung disease (other than COPD),
cardiovascular disease, diabetes mellitus or any other
metabolic diseases, cancer, oral corticosteroid use in
the last 6 months, and/or respiratory tract infection
within the last 4 weeks, as determined by medical
history and patient’s list of medication. Presence of
COPD was defined according Global Initiative for
Chronic Obstructive Lung Disease (GOLD) 2009 COPD
guidelines (www.goldcopd.org). Inclusion criteria for AATD
subjects were ZZ or SZ genotype with or without history
of COPD, whereas control subjects genotype were
MM or MZ genotype. AATD patients were grouped into
3 categories, AATD with COPD receiving augmentation
therapy (AATD+AUG, n = 6), AATD with COPD not
receiving augmentation therapy (AATD–AUG, n = 6), and
AATD with normal lung function (AATDPFTnorm, n = 4).
Control COPD patients (with normal α1-antitrypsin
concentration levels, n = 7) and healthy control subjects
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(n = 6) were recruited by advertisement within the
Southern California region. Healthy control subjects
were matched for age, sex, and claimed to not participate
in regular structured exercise (i.e. running, cycling, etc.)
or sport activity. All participants were screened for
α1-antitrypsin genotyped from a blood sample and had
circulating AAT concentration measured (Biocerna LLC,
Gaithersburg, MD) (Table 1). All subjects, except for some
in the non-AATD COPD group, indicated they were
either no longer smoking (at least > 1 year) or had never
smoked. Within the non-AATD COPD group, 57% of the
subjects were current smokers (Table 2).
All subjects provided verbal and written informed
consent prior to participation in the study. The study
was approved by the Human Research Protection
Program at University of California, San Diego, and was
conducted in manner consistent with the Declaration of
Helsinki.
Experimental design and exercise testing
Each individual was studied over a two-day period. On
the first day, subjects provided a small blood sample
(5 ml via venipuncture) for assessment of hemoglobin
concentration, genotyping and measurement of circulating
AAT, and baseline concentration of serum for cytokines.
Baseline assessment of venous cytokines were obtained on
both testing days (Study day 1 and day 2) in order to
evaluate what influence, if any, prior exercise testing
may have on basal serum cytokines on the following day
(i.e. second day of the study). Spirometry was used to
assess airway obstruction using a Keystone dry-rolling
seal spirometer (S&M Instruments, Louisville, CO, USA).
Table 1 Anthropometric, medication and liver function data of subject groups
AATD + AUGa AATD + AUGb TD PFTnormc non-AATD COPDd Healthye
Lung health classification COPD COPD Normal COPD Normal
Genotype PiZZ PiZZ (PiSZ = 1) PiZZ PiMM PiMM (PiMZ = 1)
Number of subjects (m,f) 6 (3,3) 6 (2,4) 4 (1,3) 7 (4,3) 5 (3,2)
Age (years) 56 ± 4 63 ± 5 55 ± 5 64 ± 2 56 ± 1
Height (cm) 177 ± 3 170 ± 4 172 ± 5 167 ± 4 172 ± 5
Weight (kg) 80 ± 10 83 ± 13 77 ± 9 82 ± 8 86 ± 10
DXA body fat (%) 32 ± 4 37 ± 3 33 ± 7 30 ± 4 32 ± 5
Lean body mass (kg) 54 ± 6 52 ± 8 51 ± 7 57 ± 5 58 ± 7
Body mass Index (kg/m2) 25 ± 2 28 ± 3 26 ± 3 29 ± 2 29 ± 2
Fat-free index (kg/m2) 17 ± 1 18 ± 2 17 ± 2 20 ± 1 19 ± 1
Lean body mass (DXA) (kg) 49 ± 7 51 ± 7 48 ± 7 53 ± 5 54 ± 6
Thigh mass (DXA) (kg) 16 ± 2 13 ± 2 16 ± 2 15 ± 1 16 ± 2
Medication
No prescribed meds 0% 0% 100% 14% 60%
AAT Augmentation Therapy 100% 0% 0% 0% 0%
Bronchodilator 100% 100% 0% 86% 0%
Inhaled corticosteriods 83% 83% 0% 71% 0%
Oxygen 33% 0% 0% 29% 0%
Diuretics 0% 17% 0% 14% 0%
Anti-inflammatory 0% 0% 0% 0% 0%
Anti-depressive 0% 17% 0% 29% 0%
β-blockers 33% 33% 0% 29% 40%
Serum liver function tests
Total Bilirubin (mg/dL) 0.48 ± 0.06 0.50 ± 0.12 0.45 ± 0.09 0.37 ± 0.05 0.51 ± 0.12
Albumin (g/dL) 3.80 ± 0.17 3.45 ± 0.15 3.80 ± 0.12 3.77 ± 0.11 3.82 ± 0.06
Alanine Aminotransferase (U/L) 42.3 ± 15.2 28.5 ± 3.4 41.0 ± 12.7 23.4 ± 5.3 30.6 ± 2.9
Serum AAT level (mg/dl) 96 ± 22b,c <20 ± 0a,d,e <20 ± 0a,d,e 113 ± 11b,c 109 ± 12b,c
Data are mean ± SE. AATD, alpha-1 antitrypsin deficient; AUG, augmentation therapy; PFTnorm, pulmonary function testing normal; AAT, alpha-1 antitrypsin; COPD,
chornic obstructive pulmonary disease; DXA, dual-energy x-ray absorptiometry; m, male; f, female; Significance difference between group is denoted as follows, ‘a’
different that AATD + AUG, ‘b’ different that AATD-AUG, ‘c’ different compared to AATD PDTnorm, ‘d’ different compared to COPD, ‘e’ different compared to Healthy.
In all cases, significance is p ≤ 0.05.
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Lean body mass was measured via dual-energy x-ray
absorpometry (DXA), and maximal exercise testing was
performed using two different exercise modalities, 1) a
single-leg knee-extensor exercise (KE), and 2) standard
two-legged bicycle exercise. Use of the single-leg KE
ergometer has been previously reported by us [37-39] and
allows patients with cardiopulmonary disease to perform
moderate- to high-intensity muscular work in the presences
of limited pulmonary and/or cardiac reserve capacity –
allowing assessment of skeletal muscle responses to
exercise which otherwise would be severely limited with
whole body exercise. Further description of KE exercise
and cycle ergometry are provided in Additional file 1.
On Study day 2, subjects had a muscle biopsy and
blood sampling performed before and after KE exercise
(60 min at 50% of maximal KE determine on day 1). Muscle
biopsy from the vastus lateralis muscle (described in
Additional file 1) prior to exercise was obtained from
the non-exercising leg, while the muscle biopsy post-
exercise was obtained 4 hours after the single-leg KE exer-
cise on the exercised leg. Prior to exercise, femoral venous
catheter was inserted and secured in the leg to be exercised.
Radial arterial catheter was placed in the non-dominant
arm. Arterial and venous blood was obtained (in duplicate)
at rest, after which samples were obtained at 10 min
intervals during the 60 minute KE exercise, followed
by blood draws at 30 minute intervals for up to 4-hours
post exercise. The 4-hour time point was principally
selected based on data demonstrating that peak muscle
IL-6 expression occurs between 4–8 hours post exercise
[40]. Given that circulating expression of other cytokines
(e.g. TNFα and IL-1β) have also been shown to elevated
between 1 and 24-hour post exercise [25,40] it was
reasoned that examining muscle up to 4 hours post
exercise would be an appropriate time to allow muscle
levels to be altered.
Blood sampling and handling
Arterial and venous blood was collected using aseptic
technique in serum separator vacutainer tubes (Kendall
HealthCare Monoject; Fisher Scientific #22029312) and
allowed to clot at room temperature for 20 minutes.
Thereafter, blood samples were centrifuged at 3,000 RPM
(at 4 C) for 13 minutes. Serum was decanted, aliqouted
and stored at −80 C until processed.
Cytokine assessment
For each cytokine, the venous blood from Study day 2 were
compared against pre-exercise venous blood obtained on
Study day 1 (screening day) to determine if maximal
exercise testing from the previous day significantly altered
baseline cytokine concentration on Study day 2. No
significant differences in basal expression were observed
between venous samples obtained on Study day 1 vs.
day 2 (coefficient of variation [CV] for IL-1β = 0.55,
IL-6 = 0.50, TNFα = 0.25, CRP = 0.29), nor were differ-
ences found among the basal cytokine concentration
between duplicate measures of either arterial (average
Table 2 Pulmonary function, exercise capacity and smoking history of subject groups
AATD + AUGa AATD-AUGb AATD PFTnormc non-AATD COPDd Healthye
FVC (liters) 3.85 ± 0.42 2.88 ± 0.16c 4.27 ± 0.64e 2.80 ± 0.32c,e 3.96 ± 0.57d
FVC (% pred) 88 ± 6c 79 ± 5c 109 ± 6e 77 ± 8c,e 95 ± 6d
FEV1 (liters) 1.23 ± 0.25c,e 1.35 ± 0.22c,e 3.22 ± 0.47e 1.49 ± 0.11c,e 3.07 ± 0.35d
FEV1 (% pred) 35 ± 5c,e 47 ± 7c,e 107 ± 4e 54 ± 7c,e 93 ± 4d
FEV1/FVC 31 ± 3c,d,e 47 ± 7c,e 76 ± 7c,e 56 ± 4c,e 79 ± 2d
FEV1/FVC (% pred) 40 ± 4c,d,e 61 ± 10c,e 97 ± 2e 71 ± 6c,e 99 ± 3d
Bike (two-legs) exercise
Watts 62 ± 6c,e 46 ± 11c,e 176 ± 47d,e 70 ± 11c,e 126 ± 17d
VO2peak (L/min) 1.02 ± 0.11c,e 0.69 ± 0.13c,e 2.07 ± 0.51d 1.16 ± 0.12c,e 1.71 ± 0.25d
VO2peak (ml/kg/min) 12.6 ± 0.5c 9.5 ± 1.1c,e 26.9 ± 5.6d,e 14.9 ± 1.7c 20.3 ± 3.3
Knee extensor (single-leg) exercise
Watts 25 ± 3c 21 ± 7c 59 ± 23d,e 21 ± 3c 26 ± 1
Smoking history
Never 17% 0% 25% 0% 0%
Ex-smoker 83% 100% 75% 43% 100%
Current 0% 0% 0% 57% 0%
Data are mean ± SE. AATD, alpha-1 antitrypsin deficient; AUG, augmentation therapy; PFTnorm, pulmonary function testing normal; AAT, alpha-1 antitrypsin; COPD,
chronic obstructive pulmonary disease; FVC, forced vital capacity; FEV1, forced expiratory volume at 1 sec; VO2peak, peak oxygen consumption during exercise.
Significance difference between group is denoted as follows, ‘c’ different compared to AATD PFTnorm,‘d’ different compared to COPD, ‘e’ different compared to
Healthy. No differences with respect to AATD + AUG ‘a’ or AATD-AUG ‘b’ were found. In all cases, significance is p ≤ 0.05.
Olfert et al. BMC Pulmonary Medicine 2014, 14:106 Page 4 of 14
http://www.biomedcentral.com/1471-2466/14/106
CV for IL-1β = 0.51, IL-6 = 0.35, TNFα = 0.22, CRP = 0.21)
or venous blood (average CV for IL-1β = 0.30, IL-6 = 0.41,
TNFα = 0.21, CRP = 0.12). Accordingly, the resting arterial
and venous values were averaged to yield one resting
arterial and venous serum values, respectively, which were
used for all further statistical analyses. Additional descrip-
tion of the qualitative assessment of the methodology, vari-
ation, and minimal detection levels of the cytokine assays
are provided in the Additional file 1: Methods.
Statistical analyses
Demographic, anthropomorphic, lung function and exercise
data were compared across subjects groups using ANOVA
with Fisher’s PLSD post hoc testing when significant main
effects were observed. Kruskal-Wallis test revealed cytokine
data were not normally distributed across the subject
groups, therefore cytokine data were square-root trans-
formed and then analyzed using a 2-way mixed effect
ANOVA model with repeated measures experimental
design using either JMP/Pro V10 (SAS Inst. Inc.,
Cary, NC) or StatView Analysis (v5.0.01 SASS Inst.
Inc., Cary NC). Post-hoc testing was performed when
a significant overall F-ratio was achieved. Correlations
were performed using a Spearman Rank Test. In all
cases p ≤ 0.05 was used to establish significance. All
data shown are mean ± SE, unless otherwise indicated.
Results
Subject characteristics
Group data depicting demographic, anthropometric, and
serum liver function tests are shown in Table 1. Spirometry
data and maximal exercise performance are shown in
Table 2. Supplemental tables are also provided to
show spirometric comparison of the single MZ sub-
ject (Additional file 1: Table S1A) and the SZ subject
(Additional file 1: Table S1B) compared to their respective
groups. All subjects enrolled completed the study,
however one subject (female in the healthy group)
was eliminated from the analysis in the study when
evidence of undiagnosed pulmonary abnormality was
found (i.e. resting arterial PO2 = 66 Torr). Healthy subjects
were well matched to all patients groups according to age,
height and weight (Table 1).
As expected, all patients with COPD had reduced
whole body aerobic capacity (i.e. VO2peak) compared to
subjects with normal lung function (Table 2). While the
healthy subjects had greater aerobic exercise capacity,
single-leg knee extensor (KE) exercise capacity was not
significantly different compared to COPD patients groups.
Total body mass, body mass index (BMI), % body fat and
lean body mass were similar between healthy and all the
COPD patients, which tends to support the idea that our
‘healthy control group’ subjects were similarly matched
based on physical (in)activity.
Subject group comparisons
Resting serum cytokines were not different for any
cytokine in venous blood obtained from Study Day 1
(measured prior to max testing) compared the following
Day 2 (resting measured prior to exercise) indicating
that previous day exercise activity had no influences
on baseline cytokines concentration levels on the following
day in our subjects (data not shown).
All measured cytokines displayed significant main effects
according to subject groups, therefore post hoc testing
for group differences were performed for each cytokine.
Non-AATD COPD patients exhibited highest circulating
concentrations for all cytokines measured (i.e. TNFα,
IL-1β, 1 L-6 and CRP) in both arterial and venous blood
compared to any subject group (Figures 1 and 2). Expres-
sion of all circulating cytokines were significantly greater in
non-AATD COPD compared to healthy controls (p < 0.05;
Figures 1 and 2), except for venous IL-6 which was not sig-
nificant (p = 0.099; Figure 2) but displayed a similar trend.
In all cases, cytokine concentrations were lower in
AATD COPD patients compared to COPD control patients
(Figures 1 and 2). Arterial IL-1β and TNFα concentration
were also observed to be lower in AATD+AUG patients
than in healthy controls (Figure 1). Similarly, both arterial
and venous TNFα levels were lower in AATD–AUG
compared to healthy controls (Figure 2). In contrast,
circulating arterial and venous CRP concentration
were elevated in AATD+AUG and AATD–AUG patients
compared to healthy controls and AATD PFTnorm, but
were significantly lower compared to non-AATD COPD
patients (Figures 1 and 2).
When comparing AATD COPD individuals ‘on’ ver-
sus ‘off ’ augmentation therapy (AATD + AUG and
AATD–AUG, respectively), we found no differences in the
circulating levels of IL-6, IL-1β or CRP (Figures 1 and 2).
However, venous TNFα was significantly greater in
AATD + AUG compared to AATD–AUG (Figure 2).
Circulating cytokine response to exercise
Mixed effect ANOVA revealed no significant main effect
for exercise (or subject group × exercise interaction) for
any of the cytokines measured in arterial blood or venous
blood. In addition, a separate mixed effect ANOVA that
only included resting and exercise data (i.e. without
post-exercise data) revealed no significant main effect for
exercise for any of the cytokines measured. A summary
depicting the group mean exercise data along with resting
cytokine concentrations for both arterial and femoral
venous blood is shown in Figure 3.
Femoral venous-minus-arterial (v-a) difference and
skeletal muscle expression
TNFα was the only cytokine showing significant ANOVA
main effect for v-a difference (ANOVA p < 0.05). Post hoc
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testing revealed TNFα v-a difference was greater in
AATD + AUG compared to AATD–AUG and COPD
control groups (p < 0.05), along with similar tendency
for Healthy subjects (p = 0.0516) (Figure 4).
In skeletal muscle, only TNFα was found to exhibit a
significant ANOVA main effect (Figure 5). Skeletal muscle
TNFα was greater in AATD–AUG subject compared
to all other groups (Figure 5). Skeletal muscle expres-
sion for IL-1β was below the minimal detectable level
of our assay (i.e. 0.08 pg/mL) and therefore unable to
be determined.
Exercise exerted no significant effect on the skeletal
muscle concentration of any cytokines measured (Figure 5).
Correlation of circulating cytokines to airway obstruction
In AATD COPD patients (i.e. AATD + AUG and AATD-
AUG groups) we find no evidence to support a correlation
between circulating arterial cytokines and the degree of
Figure 1 Arterial serum levels of IL-1β, IL-6, TNFα and CRP obtained under resting conditions (black bar), every 10 minutes during
1-hour single-leg knee extensor exercise at 50% of maximal exercise capacity (gray bars), and every 30 minutes (up to 4 hours)
during recovery post exercise (white bars), in COPD individuals with alpha-1 antitrypsin deficiency receiving augmentation therapy
(AATD + AUG), AATD individuals not receiving augmentation therapy (AATD-AUG), AATD individuals with normal pulmonary function
(AATD PFTnorm), non-AATD COPD patients (COPD), and age-/activity-matched controls with no lung disease (Healthy). Significant ANOVA
main effect for group differences are shown above each graph. In all cases, significance is determined as p < 0.05.
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airway obstruction (Figure 6). In nonAATD COPD
patients, there was a trend for increasing TNFα (p = 0.09),
IL-1β (p = 0.57) and IL-6 (p = 0.16) in association with
worsening FEV1/FVC, but no significant correlation was
observed (Figure 6).
Discussion
The main findings of this study are, 1) AATD patients with
COPD have lower circulating cytokines concentration
compared to non-AATD COPD patients, 2) patients with
AATD COPD receiving augmentation therapy have lower
TNFα expression in skeletal muscle and a greater venous-
minus-arterial difference for circulating TNFα (suggesting
net efflux of TNFα from the skeletal muscle) compared
to AATD COPD patients not receiving augmentation
therapy, and 3) 60-minutes of sustained moderate-intensity
exercise had no significant effect for any of the measured
cytokines. These changes were seen reproducibly across
sequential arterial and venous blood samples within
individual subjects and across patient subject groups.
Figure 2 Femoral venous serum levels of cytokines from same conditions and subject groups in Figure 1. Significant ANOVA main effect
for group differences are shown above each graph. In all cases, significance is determined as p < 0.05.
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Systemic inflammation in AATD and non-AATD COPD
Large scale cross-sectional studies have documented
the association between systemic inflammation and
reduced lung function in patients with COPD [41] as well
as in healthy subjects [42]. Our data, showing elevated
circulating concentrations of IL-1β, IL-6, TNFα and CRP
are consistent with both clinical and laboratory evidence
showing increased chronic systemic inflammation in
COPD. More importantly, our data show that this finding
cannot be generalized to patients with COPD resulting
from AATD. In all cases, cytokine concentration was
lower in AATD individuals (with or without lung disease)
compared to the non-AATD COPD patients (Figures 1
and 2). When compared to healthy control subjects, only
CRP was elevated in AATD COPD patients, but this
increase was still lower compared to CRP in non-AATD
COPD patients (Figures 1, 2 and 3).
The elevated CRP concentration seen in our AATD
subjects with COPD may lend support to the idea that
polymers from abnormal variants of α1-antitrypsin alleles
are pro-inflammatory [43-45]. However, since AATD
individuals with normal spirometry (AATDPFTnorm)
did not have elevated CRP, and yet exhibit a similar
low circulating AATas AATD-AUG with COPD (Table 1),
it seems more likely the elevated CRP is associated with
the pathophysiology of the COPD sequelae rather than a
response to polymers associated with α1-antitrypsin allele
variants. It is surprising, however, that AATD COPD
patients had lower blood levels of CRP (compared to
non-AATD COPD patients, Figures 1, 2 and 3) but yet
exhibited similar, if not greater, airway obstruction (Table 1).
Based on the existing literature [46,47], it might have been
expected that individuals with the worst lung function
would have the greatest increases in circulating CRP.
Figure 3 Summary comparison of arterial (black bars) and femoral venous (gray bars) serum levels for cytokines at rest (R) and during
exercise (E) highlighting the observation of, 1) no significant response to exercise and, 2) no significant difference between arterial
and femoral venous serum levels among subject groups. ‘R’ values are averaged data from rest and post-exercise ‘recovery’ time points
shown in Figures 1 and 2. ‘E’ values are averaged for all exercise time points shown in Figures 1 and 2. Overall subject group differences are
clearly present (as shown in Figures 1 and 2), but statistical notation of these differences are not recapitulate on this summary figure.
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One explanation may be that plasma CRP is produced
principally in hepatocytes and individuals with AATD
(in addition to developing emphysema) can also develop
cirrhosis of the liver, potentially leading to liver failure as a
result of excess deposition of abnormal α1-antitrypsin
protein in the liver. But we found no evidence of liver
dysfunction in any of AATD subjects (Table 1). There
are only few small studies that have evaluated the risk
of cardiovascular events in AATD individuals [48-50].
Despite conflicting results [51], there is evidence of
altered vessel elasticity (e.g. increased aortic wall stiffness)
that supports elevated risk of cardiovascular disease
[49,50], as well as occult musculoskeletal changes [48],
both of which could contribute to the morbidity and
mortality in AATD individuals. Although the severity
of pulmonary dysfunction appears worse in AATD patients
with COPD (compared to non-AATD COPD patients),
circulating biomarkers for inflammatory cytokines (other
than CRP) in AATD COPD patients were similar to
healthy subjects. These data highlight the fact that it
cannot be assumed that the inflammatory sequelae
for COPD are similar between AATD and non-AATD
COPD patients. Indeed, while non-AATD COPD patients
are often found to have elevated circulating TNFα
concentration [see meta-analysis review, Ref [41]], as
seen in our data (Figures 1 and 2), we find no significant
evidence of elevated circulating TNFα in AATD COPD
individuals - even with greater degree of airway obstruc-
tion (Figure 6). Previous studies examining inflammatory
biomarkers in PiZZ COPD patients report similar obser-
vations [9,52]. Collectively, these data oppose the idea that
systemic inflammation contributes to the underlying lung
pathology in patients with AATD COPD, as AATD COPD
individuals with the greatest deficits in lung function
exhibited minimal evidence of systemic inflammation.
These data also add to the recognition that while the
clinical manifestations of COPD are often very similar,
the underlying mechanism and pathology are much
less easily defined or even homogeneous in nature. It
is important for future COPD research to evaluate
the origins of the heterogeneity observed in patients
with COPD before we can better understand how best
to treat and individually manage patients suffering
from COPD.
Effect of augmentation therapy on inflammatory
cytokines
In general we found no significant differences between
AATD patients with COPD receiving augmentation therapy
(AATD+AUG) compared to those not receiving augmen-
tation therapy (AATD–AUG). However, it was observed
that AATD+AUG patients had slightly greater circulating
TNFα in venous blood compared to AATD–AUG patients
(Figure 2). A significant difference in circulating TNFα
Figure 4 Box plot showing femoral venous-minus-arterial (v-a) cytokine values obtained from mean venous and arterial data represented for
groups in Figures 1 and 2. Venous values are obtained from the femoral vein, therefore v-a > 0 imply muscle efflux of cytokines, whereas v-a < 0 imply
muscle uptake. Zero v-a values imply no muscle involvement. Box boundaries show 25th and 75th percentile, while whisker bars represent 10th and 90th
percentile. All observations >90th percentile are individually represented as open circle (ο) data point. Group median is shown as center line within the
box. Post-hoc testing was only performed on TNF-α, where a significant ANOVA main effect (p < 0.05) was observed. * indicates p < 0.05 compared to
AATD + AUG, ‡ p = 0.0516 compared to AATD+ AUG.
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between these groups was also seen when calculating the
venous-minus-arterial difference in TNFα (Figure 4). The
latter finding (i.e. positive TNFα v-a difference due to
greater femoral venous versus arterial concentration)
suggests that there is net outflow or ‘spillover’ of
TNFα into the circulation from skeletal muscle in
AATD + AUG patients. In contrast, the negative TNFα
v-a values (i.e. higher arterial versus femoral venous
concentrations) seen in AATD–AUG subjects (Figure 4),
suggests a net muscle uptake of TNFα in these subjects.
This finding is supported by elevated TNFα expression in
skeletal muscle of AATD–AUG subjects that is not
seen in AATD + AUG subjects (Figure 5). However,
the interpretation of this finding still remains somewhat
ambiguous, given that similar negative TNFα (v-a) values
were seen in the control groups (i.e. AATDPFTnorm,
non-AATD COPD, and Healthy), yet only AATD–AUG
subjects exhibited elevated skeletal muscle TNFα.
CRP was the only other cytokine found to be greater
in AATD patients with COPD compared to controls
(as previously discussed). But for CRP there was no
difference between AATD individuals ‘on’ or ‘off ’ augmen-
tation therapy, suggesting that AAT replacement therapy
had no effect on circulating CRP concentration. Taken
together, it remains uncertain what clinical effect, if
any, that differences in circulating TNFα and CRP
may actually exert between AATD patients ‘on’ versus
‘off ’ augmentation therapy.
Inflammatory response in skeletal muscle
Several studies have reported on the cytokine responses
in skeletal muscle of COPD patients. [53-55], but to our
knowledge no studies have examined skeletal muscle in
AATD individuals or what effect augmentation therapy
may have. Our data suggest that there is elevated TNFα
in the skeletal muscle of AATD–AUG subjects (Figure 5),
which, to some extent, supports the implication of an
active musculoskeletal inflammatory process. But, as
previously mentioned for circulating cytokines, the
importance of this finding remains somewhat unclear
in muscle, since 1) increases in other proinflammatory
cytokines were not observed in the skeletal muscle of
this patient group, and 2) a similar increase in muscle
TNFα was not also observed in the non-AATD COPD
patient group who also had evidence of elevated systemic
inflammation. But, whether or not TNFα is typically
elevated in skeletal muscle of patients with COPD
remains controversial. While some studies report elevated
muscle TNFα expression [28,54], others show no change
[56,57] or decreased TNFα [53]. These discrepancies
might be explained by heterogeneity in patient population
(as we show), by differences in study design, and/or
in the sensitivity of the assay(s) that are used to measure
TNFα.
*
Figure 5 Skeletal muscle cytokine expression (normalized to
total muscle protein) from muscle biopsies of vastus lateralis
muscle before and after the 60-minutes of single-leg exercise.
Pre-exercise biopsy was obtained on non-exercising leg prior to exercise,
while post-exercise biopsy was obtained 4-hours post-exercise on the
exercising leg. We provide indication where detection of cytokines fell
below the minimal detectable limit (<mdl) of the assay, i.e. all samples
for IL-1b (therefore no data shown) and for some samples in IL-6.
Post-hoc testing was only performed on TNFα, where a significant
ANOVA main effect (p < 0.005) was observed. No significant main effect
was observed for IL-6, therefore post-hoc testing between groups was
not performed. * indicates p < 0.05 compared to all other groups.
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Exercise and inflammation
In healthy individuals, strenuous exercise elicits an
acute phase inflammatory response that is rapidly
counter-balanced by anti-inflammatory cytokines [25].
This acute phasic response is actually beneficial and
helps to maintain a strong and healthy immune system.
But there has been concern that habitual exercise in
COPD patients may superimpose an added inflammatory
burden that may prove more harmful than good [58]. Our
data, using moderate-intensity exercise (for 1-hour) at
approximately 50% of individual’s maximal aerobic power,
finds no evidence of exercise-induced inflammatory
stress in either AATD patients (with no underlying
systemic inflammation) or non-AATD COPD patients
(which had evidence of chronic systemic inflammation).
This is consistent with other data reporting acute
inflammatory responses to exercise in patients with COPD
[59], and more generally with large-scale epidemiologic
studies that have repeatedly established the benefits of
exercise in maintaining health and longevity. Indeed,
exercise capacity is touted to be the best predictor of an
AATD individual’s health status (better than high-resolution
computed tomography or lung function assessments)
[60], and our data finds no evidence to suggest that exercise
activates or exacerbates either acute or chronic inflamma-
tory pathways in either AATD or non-AATD COPD
patients. To the contrary, AATD individuals with normal
spirometry had far greater functional exercise capacity
(seen with both cycle ergometry and KE exercise, Table 1),
which could suggest that maintaining one’s aerobic
capacity may be protective for COPD progression.
However, based on our study design, we cannot know
whether aerobic exercise is truly protective for disease
progression, or if this observation is simply a coincidence
based on the small subset of the individuals in our study.
Study limitations
When making cross-sectional group comparisons, it
must be recognized that our relatively small subject
population (n = 4–7 subjects per group) combined with
Figure 6 Correlation between circulating arterial cytokines and airway obstruction for AATD COPD patients (i.e. AATD + AUG and
AATD-AUG groups shown as shaded circles) and for non-AATD COPD patients (open triangles). Dotted regression line reflect data for
AATD COPD, whereas dashed regression line reflect data for non-AATD COPD.
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multiple comparisons could increase the potential of
identifying spurious relationships. But, our study also
included a repeated measure study design, in which each
subject served at their own control. Indeed, from each
subject we obtained 34 temporally independent blood
measurements (17 arterial, 17 femoral venous) and 2
muscle biopsy measurements (one pre-exercise and one
post-exercise). Given the number of individual measure-
ments made in each subject, the statistical power for the
repeated measures relating to exercise response is
high (i.e. β >0.95). Based on the large number of individual
blood measurements made, we also have a high degree of
confidence in the individual mean values obtained for each
subject. While this does not eliminate the concern for
variability among small total number of subjects within
each group (i.e. the cross-group comparisons), there is
greater confidence in the accuracy of the absolute mean
values for each subject that helps to increase confidence in
the interpretation of the cross-sectional data. For example,
comparing variability in Figures 1 and 2 (which report
individual rest and exercise data points) to Figure 3
data (which reports a summary of mean values for rest and
exercise data, respectively) it is clear the lower variability
evident in Figure 3 provides greater confidence in the
evaluating across patient groups differences that are
mirrored in Figures 1 and 2. Nonetheless, it must be stated,
given the small number of patients in each group, any
cross-sectional interpretation must be view with caution.
Conclusion
These data establish that AATD patients with COPD
do not experience the same inflammatory cytokine
response as that typically seen in non-AATD COPD
patients. However, it is evident the circulating the CRP
(albeit lower compared to that seen in non-AATD COPD
patients) is elevated in AATD COPD patients compared
to controls subjects with normal lung function. In general,
augmentation therapy did not appear to alter circulating
cytokine concentrations, except for TNFα. AATD COPD
patients on augmentation therapy exhibited a positive
venous-minus-arterial TNFα serum difference, whereas
those off augmentation therapy exhibited a negative
venous-minus-arterial TNFα difference. This negative v-a
difference (suggesting muscle sequestration of TNFα) in
AATD COPD subjects not receiving augmentation
therapy correlated with significantly higher muscle concen-
tration of TNFα compared to patients on augmentation
therapy. While these data cannot establish a cause-and-
effect relationship, they suggest that patients receiving
augmentation therapy may have net efflux of TNFα
from the skeletal muscle. Lastly, our data indicate that
exercising for 60 minutes at 50% of maximal work
capacity does not significantly increase expression of
circulating inflammatory cytokines. Collectively, these data
suggest that systemic inflammation is not simply a
“spill over” function of pathophysiology associated
with destruction of lung tissue per se, but rather suggests
that compounds or mechanism(s) associated with envir-
onmental risk factors (such as tobacco smoke) likely play
a principle role in eliciting the inflammation reaction.
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